Please Follow us on Gab, Minds, Telegram, Rumble, Gettr, Truth Social, Twitter
PHARMA giant AstraZeneca has requested that the European authorization for its COVID-19 vaccine be pulled, according to the EU medicines regulator.
In a posting on the European Medicines Agency’s website (EMA) Wednesday, the regulator stated that the approval for AstraZeneca’s Vaxzevria had been withdrawn “at the request of the marketing authorization holder.”
AstraZeneca’s COVID-19 vaccine was first approved by the EMA in January 2021. Shortly thereafter, concerns grew about its safety, when dozens of countries suspended the vaccine’s use after blood clots were detected in immunized people. The EMA, at that time, concluded AstraZeneca vaccination risk of blood clots were rare. Nevertheless, doubts remained.
AstraZeneca's covid vaccination clinical trials and covid vaccination manufacturing were done in the U.S. although its vaccinations were never administered in the U.S.
In Spring 2021, AstraZeneca vaccinations, manufactured at a contaminated Baltimore plant, were shipped to Canada.
Canadian AstraZeneca vaccination-injured contacted CDM.Press after they successfully linked their AstraZeneca vaccination vials to the Baltimore plant.
When Britain authorized AstraZeneca in 2021, researchers had refused to acknowledge manufacturing mistakes. Insufficient data about how well the AstraZeneca vaccine protected older people led some countries to initially restrict its use to younger populations.
Billions of doses of the AstraZeneca vaccine were distributed to poor countries through a U.N. co-ordinated program because it was cheaper and easier to produce.
But studies later suggested that the pricier messenger mRNA vaccines made by Pfizer-BioNTech and Moderna provided better protection against COVID-19 and many countries switched to those shots.
To date, the FDA in the U.S. has not officially recognized the irrefutable links between the mRNA vaccines and vascular and neurological injuries, which the FDA, NIH, NIAID, and CDC have known about since January 2021.
The U.K.'s national coronavirus immunization program in 2021 heavily relied on AstraZeneca’s vaccine, which was largely developed by scientists at Oxford University with financial government support.
Britain later resorted to buying the mRNA vaccines for its COVID booster vaccination programs and the AstraZeneca vaccine is now rarely used globally.
